Marie Myers is the CFO of UiPath and is based in the company's new Houston office. Courtesy of UiPath

It's safe to say that Marie Myers — CFO of UiPath, which opened its 71-person office in Houston earlier this year — loves her job.

The robotics process automation company, which was founded in Romania before moving its headquarters to New York City last year, is in major growth mode. At the helm of the financial side of things is Myers, who has over 20 years of experience in technology.

When Myers was working on a spinoff project for HP, she started seeing the difference software automation makes on a company's bottom line.

"I realized RPA was the fastest way to drive efficiencies, so I started building bots," she tells InnovationMap. "During that time, I came across UiPath and I saw how impressive their technology was. In my more than two-decade career, I hadn't really come across a technology that I felt that had such an impressive impact in such a short time."

She drank the UiPath Kool-Aid, and when the company came to her adopted hometown of Houston to open an office to be its central, Midwestern location, she leapt at the opportunity to join the team. Now, with several months under her belt in the position and a growing office, Myers speaks with InnovationMap about the company's growth and the revolution that RPA is having in business.

InnovationMap: You've been in your role since January, but you've been in tech for a while now. How has the transition been for you?

Marie Myers: This has been one of the most exciting times for my career. I've been in tech for about two decades. I started with Compaq — quite an incredible company that started right here in Texas. It was a very famous startup in its own time, and I had a chance to be a part of that wave, which was really incredible. Then, it got bought out by HP, and then I pivoted and spent a lot of time in Silicon Valley for a couple decades.

I got involved in robotics process automation quite by happenstance about four years ago when HP decided to split. I was involved in setting up a company from the finance and legal perspective. I got challenged to drive some cost efficiency, so I turned to RPA as a means to drive some of that impact within my own organization of a couple thousand folks.

When the opportunity came up to be CFO for UiPath, I really jumped at it because it filled two important things for me. I wanted to be a leader of a finance organization and team. Secondly, I wanted to do something where I was really passionate about the technology. When I think about RPA, the world lights up for me. It's truly transformative.

IM: How did UiPath decide to open a Houston office? What made the city a key market?

MM: Houston — particularly Texas — are both important for us, from a customer perspective. We have some of our larger companies in the country here in Texas, so it was a natural place to look to build capability. Secondly, we're impressed with the overall quality of the market and the availability of different skills here as we build out our company.

IM: What are some goals UiPath has for its new Houston office?

MM: Overall, one of the key goals is to establish a strong Midwest presence for the company. Texas is an ideal location if you think about it for customers that range from the East to the West. Being in the middle is a good, central location. Also, as we grow and expand in Latin America, it's another interesting spot for us. So, one, to ensure that we are able to support the growth needs of the company throughout the United States and leverage the strategic location that Texas has.

I think the other goal is to build some of the core skills we need for the overall organization as we grow in the United States. UiPath is a relatively new player in the U.S., only been here a couple of years.

Finally, we've got terrific customers here, so what's important is to continue to support and nurture those customers. We have a big presence in oil and gas and the support companies within energy.

IM: Tell me about the Academic Alliance and how the company engages with students.

MM: Basically, we offer free training to the universities so that students can get first-hand experience for robotics process automation, which is part of our broader commitment we've made to ensure RBA is available in an open, democratized way.

We are big proponents of supporting students, and we had a great intern program this last summer. We had a double-digit number of interns — I think the largest population in the U.S. We love the fact that we have this access to universities that we can easily tap into.

Just a couple weeks ago we ran UiPath's first-ever hackathon for students in the United States. We had over 50 participants.

We're really excited about building out the ecosystem with the universities and the students here in Houston.

IM: What sort of misconceptions do you encounter within automation?

MM: First and foremost, a lot of it is misconceptions about RPA replacing jobs. I'd say it's a shift in the workforce — I witness this first hand because I had a team where we implemented and built bots. What happens is you create capacity and end up creating new jobs. You have roles of managing bots, bot controllers, bot librarians — these are roles that fundamentally didn't exist five years ago.

IM: What advice do you have for women in tech?

MM: I think it's so critical for women to be in the driving seat and in the forefront of technology. I have two daughters and I'm adamant about how they are exposed to robotics. I did a coffee talk in Houston not too long ago, and I really challenged the women to get out there and get digitally literate. It's really important as women that we don't let ourselves fall behind on technology and how they are impacting both our work and our families. So, staying informed, no matter how you do that — reading, podcasts, news. Another way is to join and network with associations. Myself and another woman important in this space are looking to create a network for women in automation. We want to build a group that will allow women to look for jobs, board roles, mentors, etc. in this industry.

IM: What role do you see Houston playing in the greater innovation conversation and where does the city have room to improve?

​MM: I'm a big fan of Houston. I'm Australian, but I feel like a Texas implant now. It's an incredibly diverse city, and I think that's one of its greatest strengths. You've got people from all walks of life from all parts of the world and a great education system. That creates a really unique backdrop for the technology-led era we're in. The historical strengths of the city have been predicated on the healthy oil and gas sector and medical sector — both are important industries going through major technology transformations. I think for Houston being able to capitalize on all that is a very unique opportunity. It will position Houston very well for the future. You've got the right ingredients here.

Where the city is going to have to continue to build is specifically around some of these skills for the future. Artificial intelligence and having that depth of experience is an area the city struggles in. Certainly other cities like Seattle and San Francisco have tens of years of experience from companies like Google, Facebook, and Amazon that have been able to build deep AI. In Houston, that skillset is going to come more from oil and gas, where they've been building some of those skills, just not in the same breath and not in the same depth as those other cities. I think the real opportunity is to nourish and nurture this in the academic institutions and then take that talent out of the academic institutions and integrate them into the corporations.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”

10+ Houston innovation leaders in the spotlight at SXSW 2026

where to be

Houston's innovation scene will be well represented at South by Southwest (SXSW) this month.

The week-long, Austin-based conference and festival will spotlight some of the Bayou City's leaders in health care, energy, space and more. The event kicks off today, March 12, and runs through March 18. The SXSW Innovation Conference will feature keynotes, workshops, mentoring sessions and more throughout various venues in the city.

Here's who to see and when and where to find them:

March 12

Aileen Allen, venture partner at Mercury Fund

Mentor Session from 4-5:15 p.m. at Hilton Austin Downtown

Allen will host a mentoring session focused on funding, marketing, advertising, PR and the future of work.

March 13

Heath Butler, partner at Mercury Fund

SXSW Pitch-Smart Cities, Transportation, Manufacturing & Logistics from 2:30-3:30 p.m. at the J.W. Marriott

Butler will judge five innovative startups as they pitch their solutions to advance smart cities, enhance transportation systems, modernize manufacturing, transform logistics, and strengthen government infrastructure and civic operations.

Jonathan Cirtain, CEO and president of Axiom Space

The Clock is Ticking for Space - Replacing the ISS from 4-5 p.m. at the J.W. Marriott

Cirtain will discuss Axiom's pursuit of building the world’s first commercial space station.

March 14

Jesse Martinez, founder and CEO of LSA Global

SXSW Pitch-Intelligent Systems, Robotics, & Multisensory Technology from 10-11 a.m. at the J.W. Marriott

Martinez will judge five innovative startups as they pitch their technologies that aim to enhance the way people connect, communicate and share unique life experiences with those around them in a digital ecosystem.

Jennifer Schmitt, head of operations at Rhythm Energy

Powering Texas with Reliable Integrated High-Demand Energy from 10-11 a.m. at Marlow

Schmitt will join a panel to discuss how EirGrid, the state-owned electric power transmission operator in Ireland, is pioneering solutions as the country works toward 80 percent renewable integration by 2030.

Saki Sasagawa, director of business development for JETRO Houston

Now is Japan's Time: Leading the Future with Deep Tech from 10-11 a.m. at the J.W. Marriott

Sasagawa joins a panel that will share real-time insights from diverse perspectives on the forefront of Japan’s deep tech and IP businesses.

March 15

Bosco Lai, CEO and co-founder of Little Place Labs

SXSW Pitch Alumni: Where Are They Now? from 10-11 a.m. at the J.W. Marriott

Lai joins a panel of four former SXSW Pitch winners to share how they leveraged the platform to take their startups to the next level.

Tara Karimi, cofounder and chief science and sustainability officer at Cemvita

South by South America: The Rise of Southern Brazil Tech from 2:30-3:30. p.m. at The Line

Karimi will participate in a panel to discuss how Rio Grande do Sul, Brazil's southernmost state, is attracting elite talent and AI infrastructure and share insights on navigating the next wave of South American tech growth.

March 16

Dr. Pavitra P. Krishnamani, emergency medicine physician at The University of Texas MD Anderson Cancer Center

Viva La Revolution: How the Digital Age is Transforming Wellness from 11:30 a.m.-12:30 p.m. at Hilton Austin Downtown

Krishnamani will discuss the latest advancements and policies that can accelerate the digital age of health care, such as wearables, telehealth and artificial intelligence.

March 18

Charlie Childs, co-founder and CEO of Intero Biosystems

Spinning Out: What It Takes to Build a University Startup from 2:30-3:30 p.m. at The Line

Childs will join founders who spun their companies out of the University of Michigan to share the real story of navigating IP, early capital, team building, market validation and the “valley of death.”

Dr. James Allison, regental chair of immunology and director of The Allison Institute at The University of Texas MD Anderson Cancer Center

Dr. Padmanee Sharma, professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Beyond Checkpoints: Immunotherapy’s Next Act from 2:30-3:30 p.m. at the J.W. Marriott

Allison and Sharma will sit down with 21-year-old, Stage 4 cancer survivor Sharon Belvin and Time Magazine journalist Alice Park will discuss the future of immunotherapy and what challenges remain.

Last year, Houston startups Little Places Labs and Helix Earth won top prizes in their respective categories at the prestigious SXSW Pitch event, held this year from March 13-14. No Houston startups were named finalists to compete in this year's event.

NASA revamps Artemis moon landing program by modeling it after Apollo

To the moon

NASA is revamping its Artemis moon exploration program to make it more like the fast-paced Apollo program half a century ago, adding an extra practice flight before attempting a high-risk lunar landing with a crew in two years.

The overhaul in the flight lineup came just days after NASA’s new moon rocket returned to its hangar for more repairs, and a safety panel warned the space agency to scale back its overly ambitious goals for humanity’s first lunar landing since 1972.

Artemis II, a lunar fly-around by four astronauts, is off until at least April because of rocket problems.

The follow-up mission, Artemis III, had been targeting a landing near the moon’s south pole by another pair of astronauts in about three years. But with long gaps between flights and concern growing over the readiness of a lunar lander and moonwalking suits, NASA’s new administrator Jared Isaacman announced that mission would instead focus on launching a lunar lander into orbit around Earth in 2027 for docking practice by astronauts flying in an Orion capsule.

The new plan calls for a moon landing — potentially even two moon landings — by astronauts in 2028.

“Everybody agrees. This is the only way forward,” Isaacman said.

The hydrogen fuel leaks and helium flow problems that struck the Space Launch System rocket on the pad at NASA's Kennedy Space Center in February also plagued the first Artemis test flight without a crew in 2022.

Another three-year gap was looming between Artemis II and the moon landing by astronauts as originally envisioned, Isaacman said.

Isaacman stressed that “it should be incredibly obvious” that three years between flights is unacceptable. He'd like to get it down to one year or even less.

Isaacman, a tech billionaire who bought his own trips to orbit and performed the world’s first private spacewalk, took the helm at NASA in December.

During NASA’s storied Apollo program, he said, astronauts’ first flight to the moon was followed by two more missions before Neil Armstrong and Buzz Aldrin landed on the moon. What's more, he added, the Apollo moonshots followed one another in quick succession, just as the earlier Projects Mercury and Gemini had rapid flight rates, sometimes coming just a few months apart.

Twenty-four Apollo astronauts flew to the moon from 1968 through 1972, with 12 of them landing.

“No one at NASA forgot their history books. They knew how to do this," Isaacman said. “Now we're putting it in action.”

To pick up the pace and reduce risk, NASA will standardize its Space Launch System rockets moving forward, Isaacman said. These are the massive rockets that will launch astronauts to the moon aboard Orion capsules. At the same time, Elon Musk's SpaceX and Jeff Bezos' Blue Origin are speeding up their work on the landers needed to get the astronauts from lunar orbit down to the surface.

Isaacman said next year will see an Orion crew rendezvousing in orbit around Earth with SpaceX's Starship, Blue Origin's Blue Moon or both landers. It's similar to the methodical approach that worked so well during Apollo in the late 1960s, he noted. Apollo 8, astronauts' first flight to the moon, was followed by two more missions before Armstrong and Aldrin aimed for the lunar surface.

“We should be getting back to basics and doing what we know works,” he said.

The Aerospace Safety Advisory Panel recommended that NASA revise its objectives for Artemis III “given the demanding mission goals.” It’s urgent the space agency do that, the panel said, if the United States hopes to safely return astronauts to the moon. Isaacman said the revised Artemis flight plan addresses the panel's concerns and is supported by industry and the Trump administration.